The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A single institution retrospective review of efficacy, toxicity, and symptom burden in patients (pts) with pancreatic cancer (PaC) receiving FOLFIRINOX chemotherapy.
James Traquair Paul
No relevant relationships to disclose
Pascal J Lambert
No relevant relationships to disclose
Joel Roger Gingerich
No relevant relationships to disclose
Piotr Czaykowski
No relevant relationships to disclose
Paul Joseph Daeninck
No relevant relationships to disclose